ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SGP vs PRCT // OPERATING MARGIN

SpyGlass Pharma Inc. (NASDAQ) VS. PROCEPT BioRobotics Corporation (NASDAQ) • 15-METRIC TALLY: SGP 2 — PRCT 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SGP VS. PRCT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SGP PRCT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 63.70% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -3.08% -5.02% +1.94 SGP /fcf-yield <GO>
Operating Margin ACTIVE — -33.70% — TIE /operating-margins <GO>
Net Profit Margin — 0.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 37.20% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 3.98 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 PRCT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 72.1 57.2 +14.90 SGP /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.09B $1.16B -$75.3M PRCT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SGP REV PRCT REV SGP GROSS % PRCT GROSS % SGP FCF PRCT FCF
FY 2025 $0 $308.1M — 63.7% -$33.5M -$58.3M
FY 2024 $0 $224.5M — 61.1% -$24.0M -$103.6M
FY 2023 — $136.2M — — — -$108.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SGP // BETA —
PRCT // BETA —